OptiNose, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Stock-based compensation
Change in fair value of warrant liability
Amortization of debt discount and issuance costs
Allowance for doubtful accounts
Loss on extinguishment of debt
Gain on sale of equipment
Changes in operating assets and liabilities:
Accounts receivable
Grants and other receivables
Prepaid expenses and other assets
Inventory
Accounts payable
Accrued expenses and other liabilities

Cash used in operating activities
Investing activities:
Purchases of property and equipment
Proceeds from sale of property and equipment
Cash used in investing activities
Financing activities:
Proceeds from the sale of common stock
Proceeds from long-term debt
Proceeds from the sale of common stock and warrants
Proceeds from the issuance of common stock under employee stock purchase plan
Proceeds from the exercise of stock options
Cash paid for financing costs
Repayment of long-term debt
Cash provided by financing activities

Effects of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosure of cash flow information:
Cash paid for interest
Supplemental disclosure of noncash activities:
Fixed asset purchases within accounts payable and accrued expenses
Recognition of lease liabilities
Fair value of warrants issued
Fair value of common stock issued in connection with Pharmakon amendment
Financing costs within accounts payable and accrued expenses
Recognition of right-of-use assets and lease liabilities

Comments